DVA · DaVita Inc.

Current Thesis

The 2026 move in DVA was a narrative reversal that has already paid out, not a story still building. For years the overhang was "GLP-1 drugs shrink the dialysis pool." Late-2025 data flipped that GLP-1 use cut dialysis-patient mortality ~17%, meaning treated patients stay in the system longer and lifetime value rises. On top of that, a post-COVID census recovery and margin inflection landed in the Q1 print (2026-05-05): adj EPS $2.87 vs $2.33 est (+43.5% YoY), revenue $3.42B, and an FY26 adj-EPS guide raised to $14.10–$15.20. Shares gapped ~+22% and ran from ~$115 to a $202.69 ATH. As of 2026-06-05 spot is ~$192.16, below the average analyst PT of $193.71, ~5% off the high, with Berkshire trimming and no catalyst until the Q2 print (~early Aug). State is MATURING drifting toward SATURATED: the re-rate is spent, the tape has gone sideways, and a fresh long here is buying a completed move with no edge.

Bull Case

• Q1 2026 beat + raise (2026-05-05): adj EPS $2.87 vs $2.33 est (+43.5% YoY), revenue $3.42B vs ~$3.34B est; FY26 adj-EPS guide lifted to $14.10–$15.20. Volume, rate-per-treatment, and cost lines all printed positive variances.
• GLP-1 thesis inverted (late-2025 data): ~17% mortality reduction for dialysis patients on GLP-1s extends time-in-system; the dominant multi-year bear case is dead.
• Census inflecting up: Q1 US dialysis treatments ~7.03M (91,650/day) as post-COVID excess-mortality drag clears.
• Float + buyback mechanics: market cap only ~$12.34B on a tiny ~64M-share float; the formulaic repurchase that keeps Berkshire ≤45% structurally shrinks share count → EPS tailwind and a standing bid.
• Sell-side warming: Zacks moved to Rank #1 (Strong Buy) 2026-05-26; Deutsche Bank raised PT to $220; UBS high PT $235 (2026-05-07). Forward P/E 12.58 is cheap for mid-teens EPS growth.

Bear Case

• Price is through consensus: rating is "Hold," avg PT $193.71 under the $192 spot. The Street is no longer the marginal buyer; the median says fairly valued.
• Berkshire trimming into strength: ~1.22M shares (~$183M) sold around the Q1 window. Partly mechanical under the standstill buyback, but a two-decade holder is not adding up here.
• Move is spent: +70% YTD, ~5% off ATH, tape gone flat for three weeks. From here it needs operational upside, not multiple expansion and the next operational datapoint is ~two months out.
• Wrong vehicle for this book: beta ~0.84–0.91, defensive low-vol healthcare. It re-rates on prints and grinds; there is no mania leg to ride.
• Tail risks: Medicare dialysis rate-setting, the perennial DaVita-vs-insurer litigation, and elevated leverage all sit in the background.

Setup & Price Structure

• Spot: ~$192.16 (2026-06-05), roughly flat on the day; intraday range $191.67–$196.38. 52-wk range $101.00–$202.69.
• Valuation: P/E 18.48, forward P/E 12.58, market cap $12.34B, beta ~0.84–0.91.
• Structure: consolidating ~5% below the May ATH after the earnings gap, now sitting under the average PT after a small fade from ~$195. This is a mature uptrend digesting a gap, not a breakout off support. Managed-care peers (UNH/HUM/CVS) are weak, so there is no cluster confirmation DVA re-rated idiosyncratically on a single-name catalyst.
• Engageable levels: a pullback that holds the rising 20-week EMA (~$165) and bases, OR a clean breakout-and-retest above the $202.69 ATH on expanding volume. Mid-range at ~$192 with no near catalyst is neither.

Catalyst Calendar (next 30 days)

• None material. Q2 2026 earnings land ~early August (est. ~2026-08-04) outside the 30-day window. No FDA/PDUFA, no scheduled binary.
• Watch only for: incremental sell-side PT revisions (Deutsche Bank $220, UBS $235 already out) and any further Berkshire Form 4 filings, neither of which is a tradable catalyst.

What Would Change Our Mind

• Re-acceleration trigger: a breakout-and-retest that holds above the $202.69 ATH on volume would reopen a momentum entry strength confirming, not chasing.
• Pullback-to-support trigger: a controlled fade to the rising 20-week EMA (~$165) that bases and turns up would offer a clean MATURING-theme entry with defined risk.
• Thesis-break trigger: a weekly close below the 20-week EMA (~$165), OR a Q2 print (~early Aug) with treatments/day below Q1's 91,650 and no guidance raise, would signal the volume-recovery narrative has rolled over.
• Until one of those fires, the read stays track, do not chase at LOW conviction.

Correlation Notes

• Theme cluster is broken: managed-care/health-services peers (UNH, HUM, CVS, ELV) are soft to falling in 2026; DVA's run is decoupled and idiosyncratic, so there is no peer breakout to confirm a momentum entry.
• Closest read-through: Fresenius Medical Care (FMS) the other dialysis pure-play. Confirmation of the global census-recovery and GLP-1-neutral-to-positive thesis would show up there too.
• Macro: low beta means muted index sensitivity; the dominant driver is single-name reimbursement and census data, not the SPX tape.
• Ownership overhang: Berkshire's ~45% standstill cap and the formulaic buyback mean "Berkshire selling" headlines are partly mechanical share-count management, not pure conviction loss but they also cap the supply-removal narrative.

Catalyst note

The next genuine binary is the Q2 2026 print (~early Aug). Any entry inside 3 trading days of that date should be deferred defensive name or not, the gap risk is binary.